A multicentre prospective randomised open-label blinded end-point controlled trial of high-sensitivity cardiac troponin I-guided combination angiotensin receptor blockade and beta blocker therapy to prevent cardiac toxicity in breast cancer and lymphoma patients receiving anthracycline adjuvant therapy.
This study tests whether tablet medications called angiotensin receptor blockers (ARB) and B-blockers can prevent heart muscle injury related to chemotherapy in breast cancer patients. We will also show whether a convenient blood test (troponin I) can detect those patients at risk of heart failure.
Chief Investigator: Dr Peter Henriksen
Number and location of participating sites (by region/ country): UK
EudraCT number: 2017-000896-99
ISRCTN number: ISRCTN24439460
Funder: NIHR EME and BHF
Start and End date
Of grant award: 01 April 2017 to 31 January 2022
Of recruitment: 4 October 2017 to 30 April 2021
Current Status: In recruitment
Trial Website: The Cardiac CARE Trial
GDPR Privacy Statement: If you have participated in this study and would like to read how it complies with GDPR, please read this document.
Co-sponsor Representative: http://accord.scot/
Dr Fiach O'Mahony, ACCORD, University of Edinburgh & NHS Lothian, The Queen’s Medical Research Institute, 47 Little France Crescent, Edinburgh, EH16 4TJ; 0131 2429418; email@example.com
Dr Peter Henriksen, Edinburgh Heart Centre, Western General Hospital, Crewe Road South, Edinburgh’ EH4 2XU; Tel: 0131 242 3843; Email: firstname.lastname@example.org
Dr Morag MacLean, Edinburgh Clinical Trials Unit, University of Edinburgh, Nine Edinburgh Bioquarter, 9 Little France Road, EDINBURGH, EH16 4UX ; tel 0131 651 9914; email@example.com
ECTU involvement: Trial management / Statistics / Data base and randomisation / Health Economics.